PHARMACY

IQVIA report: Pharma market to top $1.5T by 2023
An average of 54 new active substance launches per year are expected over the next five years, and two-thirds of launches will be specialty products, lifting specialty share of spending to near 50% by 2023 in most developed markets, the report said.
Fresenius Kabi introduces leucovorin calcium injection
Fresenius Kabi's leucovorin calcium injection is the only liquid presentation of leucovorin available.

Hikma launches mitomycin for injection

Hikma has introduced mitomycin for injection, a cancer treatment that had a market value of roughly $43 million for the year ended November 2018, according to IQVIA data.
NCPA: Nearly 3,500 pharmacists voice support for DIR proposal

NCPA's efforts to build support for parts of the Center for Medicare and Medicaid Services' drug pricing rule involving DIR fees has drawn wide support among pharmacists and stakeholders.
NACDS provides recommendations for HHS’ Healthy People 2030 initiative

NACDS highlighted the role of pharmacists in its recommendations for the Department of Health and Human Services' Healthy People 2030 initiative.
Health Mart adds Jhaveri as president

Health Mart's new president Nimesh Jhaveri has more than 30 years’ experience in the pharmacy business, having started as a pharmacy technician at Walgreens as an undergraduate. He joined the organization on Oct. 31.
Upsher-Smith celebrates its centennial

As it marks a century in business, Upsher-Smith said its plans include diversifying and expanding its portfolio.
Dr. Reddy’s gets FDA nod for Tosymra

The Food and Drug Administration’s approval of Dr. Reddy's Tosymra provides a nasal spray for the acute treatment of migraine.
PhRMA balks at CMS' proposed changes to protected drug classes

The Center for Medicare and Medicaid Services’ proposed changes to protected drug classes would jeopardize coverage for beneficiaries, according to PhRMA’s comments on the agency’s proposed rule.
FDA approves new Imbruvica indication

The Food and Drug Administration’s approval of Imbruvica in combination with obinutuzumab helps reduce the need for chemotherapy.